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An unexpected benefit of functional genomic screens is that at times they answer questions that 
they were not designed to ask. A siRNA screen reported by Swanton et al. in this issue of Cancer Cell 
reveals that silencing of spindle assembly checkpoint genes facilitates mitotic slippage, resulting 
in escape from taxane-induced cell death, aneuploidy, and chromosomal instability, hallmarks of 
taxane resistance. Unexpectedly, the screen disclosed that the sphingolipid ceramide is a key regu-
lator of the taxane-mediated spindle assembly checkpoint and taxane-induced cell death. Ceramide 
metabolism thus serves as a legitimate target for modulation of taxane effect on tumors.An extensive literature indicates that 
the taxane group of anticancer drugs, 
which bind mitotic spindle elements, 
must provoke mitotic arrest to induce 
cell kill via apoptosis. Mitotic-phase 
cell-cycle arrest is normally regu-
lated by spindle assembly checkpoint 
proteins, mostly kinases, which are 
activated by microtubule-unattached 
kinetochores or by lack of sister cen-
tromere tension and are silenced upon 
correct alignment of chromosomes 
along the mitotic spindle. This function 
prevents premature advance to ana-
phase and chromosome missegrega-
tion and protects progeny cells from 
aneuploidy and chromosomal instabil-
ity (CIN) (Kops et al., 2005). Taxanes 
bind microtubules with high affinity, 
altering microtubule dynamics, thus 
aberrantly affecting tension at kineto-
chores that triggers sustained mitotic 
arrest, eventually resulting in apoptosis 
(Jordan and Wilson, 2004). A corol-
lary of this model is that mitotic slip-
page would be anticipated to prevent 
taxane-induced cell death. Employing 
a siRNA screen designed to inactivate 
all human kinases and a set of asso-
ciated proteins, Swanton et al. (2007) 
confirm that knockdown of select 
spindle assembly checkpoint genes 
suppresses paclitaxel-induced mitotic 
block and enables mitotic slippage, 
which results in reduced sensitivity to 
taxane lethality. While it has been gen-erally believed that mutations in mitotic 
checkpoint genes are by themselves 
not sufficient to induce aneuploidiza-
tion, requiring altered transcriptional 
regulation by tumor suppressors or 
oncogene products (Kops et al., 2005), 
Swanton et al. report that knockdown 
of mitotic spindle checkpoint genes 
is sufficient to cause polyploidy and 
anomalous centrosome numbers, even 
in the absence of taxane exposure. This 
unexpected finding establishes a firm 
linkage between silencing of specific 
mitotic checkpoint genes, mitotic slip-
page, aneuploidy, and CIN, hallmarks 
of the taxane-resistant phenotype. 
Consistent with this notion, previous 
data indicate that tumor cells with CIN 
do not typically arrest at mitosis after 
taxane treatment, nor do they respond 
well to these drugs in the clinic (Rob-
erts et al., 1990).
Another unexpected outcome of the 
screen was the discovery that genes 
associated with metabolism of the 
sphingolipid ceramide regulate the tax-
ane-mediated spindle assembly check-
point and taxane-induced cell death. 
siRNA inactivation of COL4A3BP, the 
gene encoding the ceramide transfer 
protein CERT (Hanada et al., 2007), 
provided a significant increase in pacli-
taxel chemosensitivity. CERT normally 
extracts newly synthesized ceramide 
from ER membranes and traffics it in 
a nonvesicular manner to the Golgi Cancer Cellapparatus for sphingomyelin synthe-
sis. CERT contains several functional 
domains that participate in this action, 
including a START domain that binds 
ceramide, a pleckstrin homology 
domain that recognizes Golgi phos-
phatidylinositol 4-monophosphate, 
and a FFAT motif that interacts with 
the ER resident protein VAP. CERT 
was recently cloned using LY-A cells 
that display defective sphingomyelin 
synthesis due to markedly diminished 
transfer of ER ceramide to Golgi. 
Overexpressing CERT reversed the 
genetic defects. Consistent with these 
observations, inactivation of CERT 
by a point mutation in COL4A3BP or 
use of the stereospecific CERT inhibi-
tor (1R,3R)N-(3-hydroxy-1-hydroxy-
methyl-3-phenylpropyl)dodecamide 
(HPA-12) caused an increase in ER 
ceramide content.
Relative to taxane sensitivity, the 
studies of Swanton et al. show that LY-
A cells are more sensitive to paclitaxel 
than LY-A cells overexpressing CERT, 
while siRNA to COL4A3BP sensitizes 
LY-A/hCERT cells to paclitaxel. Fur-
thermore, drug-resistant ADR/RES 
breast and SKOV3-TR ovarian cancer 
cells were found to have high levels of 
CERT, and siRNA to COL4A3BP sensi-
tized ADR/RES cells to paclitaxel. Con-
versely, lowering ceramide produced a 
phenotype opposite that of COL4A3BP 
inactivation. siRNA inactivation of GBA,  11, June 2007 ©2007 Elsevier Inc. 473
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dase that converts glucosyl-
ceramide to ceramide, which 
presumably lowers ceramide 
levels, reduced mitotic check-
point activity, increased drug 
resistance, and enhanced 
aneuploidy. Finally, data from 
14 evaluable patients receiv-
ing neoadjuvant paclitaxel for 
ovarian carcinoma revealed 
increased COL4A3BP expres-
sion in patients failing treat-
ment, strongly implying direct 
involvement of CERT in pacli-
taxel-mediated cell kill. Epista-
sis analysis of these data taken 
together indicates that the 
mitotic checkpoint likely func-
tions upstream of (or parallel to) 
ceramide (Figure 1).
COL4A3BP siRNA silencing 
in paclitaxel-treated cells also 
reduced cell number and syn-
ergistically increased caspase 
3/7 activity, suggesting that 
ceramide acts to enhance tax-
ane-induced apoptosis. These 
observations are consistent 
with multiple recent reports 
indicating that taxane lethality 
is associated with increased 
cellular ceramide, while ceramide 
inhibition confers taxane resistance 
(Asakuma et al., 2003; Prinetti et al., 
2006). Based on the ER topology of 
CERT function, Swanton et al. focused 
on ER stress as a source of signals for 
paclitaxel-induced apoptotic death. 
The ER stress response (also known 
as the unfolded protein response) is 
a conscripted sequence of events 
that lead to adaptation or apoptosis 
(Boyce and Yuan, 2006; Szegezdi et 
al., 2006). The ER is highly sensitive 
to stresses that perturb energy levels, 
Ca2+ metabolism, or the redox state. 
These stresses reduce ER capacity for 
protein folding, resulting in accumula-
tion and aggregation of unfolded pro-
teins. Unfolded proteins shift the ER 
chaperone Grp78 from three receptors, 
the protein kinase PERK, the transcrip-
tion factor ATF6, and the dual activity 
serine/threonine kinase and endonu-
clease IRE1. Sequential activation of 
these receptors either restores homeo-
stasis, or dependent on the extent 
of damage, promotes apoptosis, in 
part through ATF-4-mediated induc-
tion of CHOP. Although the studies by 
Swanton et al. do not examine the ER 
stress response in detail, they identify 
taxanes as stimulators of PERK auto-
phosphorylation, followed by induction 
of proapoptotic CHOP. These data are 
consistent with prior studies showing 
a correlation between CHOP mRNA 
increases and the response of primary 
breast cancer to paclitaxel (de las Alas 
et al., 2000). Given that COL4A3BP 
inactivation increased caspase activ-
ity after treatment of HCT-116 cells with 
the ER stressor tunicamycin, follow-
up studies examined the interaction 
between paclitaxel and COL4A3BP 
inactivation on ER stress. While siRNA 
to COL4A3BP or CERT inactivation 
using HPA-12 induced phosphoPERK 
to the same extent as paclitaxel, the 
combined effect of CERT inactiva-
tion and paclitaxel was synergistic. 
These studies define for the first time 
ceramide as a biochemical mediator 
of ER stress and, coupled with 
the epistasis data regarding 
the mitotic checkpoint, suggest 
that ceramide may represent 
a molecular switch between 
apoptosis and mitotic slippage 
(Figure 1).
How ceramide might dis-
criminate between apoptosis 
and mitotic slippage can only 
be speculated. The Swanton et 
al. studies define Akt kinase as 
candidate mediator of apopto-
sis/mitotic slippage. Data in the 
literature indicate that phos-
phorylation of Akt on Ser473 is 
activating, yielding antiapopto-
sis signaling in multiple systems, 
while dephosphorylation of this 
site is generally proapoptotic 
(Brazil et al., 2004). Further, Jin 
and Woodgett (2005) provided 
evidence that active Akt may 
play a role in aneuploidy and 
multinucleation. Swanton et al. 
report that paclitaxel reduces 
Akt phosphorylation on Ser473 
and Thr308 in cells destined to 
die by apoptosis, while dephos-
phorylation was absent upon 
siRNA inactivation of spindle 
assembly checkpoint genes. 
Manipulation of genes that regulate 
ceramide metabolism yielded com-
plementary phenotypes. COL4A3BP 
inactivation, which enhances pacli-
taxel-induced apoptosis, enhanced 
paclitaxel-induced Akt dephosphory-
lation, while GBA inactivation, which 
confers mitotic slippage, prevented 
dephosphorylation. These data are 
consistent with a recent publication by 
Asakuma et al. (2003) showing in renal 
cancer cells that paclitaxel reduces 
phosphoAkt(Ser473) via ceramide gen-
eration, amplifying paclitaxel-induced 
apoptosis and increasing TRAIL-
induced death. How ER ceramide lev-
els might modulate the phosphoryla-
tion status and compartmentalization 
of Akt at the plasma membrane has 
not been explored, although ceramide 
is known to regulate a set of kinases 
(KSR, PKCζ) and phosphatases 
(CAPP) that might transmit such sig-
nals (Kolesnick, 2002; Ogretmen and 
Hannun, 2004). Further, although a 
number of context-dependent media-
Figure 1. A Proposed Model Defining the Role of Ce-
ramide in the Response of Cancer Cells to Taxanes
Binding of taxanes to microtubules aberrantly engages the 
mitotic checkpoint, effecting sustained mitotic arrest. The 
two outcomes of sustained mitotic arrest, apoptosis or mi-
totic slippage, are regulated by the level of ceramide, and 
its downstream effector, Akt. While ceramide elevation is a 
known component of taxane-mediated death, the studies by 
Swanton et al. indicate an ER topology for the taxane-induced 
ceramide elevation. Sustained ER ceramide elevation coordi-
nately activates the ER stress response and inactivates anti-
apoptotic Akt, thus leading to apoptosis. Conversely, mitotic 
arrest in the absence of ER ceramide elevation shifts the bal-
ance toward mitotic slippage, with progression to aneuploidy 
requiring activated Akt. Additional studies will be required to 
formally document that the ER is the site of the ceramide in-
crease, and the role of CERT in this process.474 Cancer Cell 11, June 2007 ©2007 Elsevier Inc.
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Previewstors (c-Jun kinase, ASK1, eIF2α) have 
been implicated in linking ER stress to 
the apoptotic machinery, no coherent 
picture has emerged, making it difficult 
to currently speculate as to the con-
nection between ceramide signaling, 
Akt activation/inactivation, and these 
proapoptotic mediators (Boyce and 
Yuan, 2006).
In sum, the studies by Swanton et 
al. provide extensive new evidence, 
gleaned from diverse experimental 
strategies, that CERT, and its client 
ceramide, are integral to paclitaxel-
mediated cell death. Further, these 
studies identify ER stress as a previ-
ously unrecognized source of signals 
leading to apoptotic cell death upon 
taxane exposure. A challenge posed 
by these studies is to identify which of 
the many biochemical events likely to 
be dysregulated by prolonged mitotic 
checkpoint activity yields the ER stress 
response. An additional challenge is 
to define the mechanism by which ER 
ceramide might regulate taxane sensi-
tivity biochemically and/or pharmaco-The Polycomb Group (PcG) of pro-
teins were initially discovered in 
Drosophila as epigenetic silencers 
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Although these studies probably bring 
up more questions than they answer, 
they do provide unequivocal data that 
signaling associated with ceramide 
metabolism regulates taxane-induced 
apoptosis, the fundamental event in 
taxane-mediated tumor response.
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